Strength

2; 10; 30 mg/5mL; mg/5mL; mg/5mL

NDC

42192063004

Classification

Generic

Dosage Form

SYRUP

Route

ORAL

Last Updated

4/22/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA203375

On Market Since

2/1/2025

Pharmacological Classes

Adrenergic alpha-Agonists
Sigma-1 Agonist
Sigma-1 Receptor Agonists
Uncompetitive N-methyl-D-aspartate Receptor Antagonist
Uncompetitive NMDA Receptor Antagonists
alpha-Adrenergic Agonist

Price History

1W

0.0%

1M

-1.4%

3M

+2.2%

6M

-5.9%

1Y

N/A

3Y

N/A

5Y

N/A

All

-1.6%